Pfizer Expects $65 Billion in Sales for COVID mRNA Shots
Posted on 11/02/2021
U.S. pharma giant Pfizer Inc disclosed that it expects sales of the COVID-19 mRNA vaccine that it created with German partner BioNTech SE to reach US$ 36 billion in sales. Pfizer forecasts another US$ 29 billion in sales for 2022. These sales figures beat out Wall Street equity analyst estimates for both years. Pfizer claims to have the capacity to manufacture 4 billion doses in 2022 and has based its projections on sales of 1.7 billion doses. Pfizer splits gross profit from sales of the COVID shot in most of the world with BioNTech.
Pfizer has been able to scale up manufacturing compared to rivals Moderna and Johnson & Johnson when it comes to the COVID shots.
Booster Shots and Profits
The expected sales forecast on the COVID shots could end up accounting for 44% of Pfizer’s total revenue for the year. Pfizer is betting on having governments require annual mRNA COVID vaccinations.
Pfizer has expectations that beyond 2022 that COVID-19 vaccines will be a durable product and generate sales for years to come.
